Acadia Healthcare Q1 2026: An Adjusted Beat, A GAAP Whisper, And A Stock That Sold The Print
ACHC's 8-K showed Q1 2026 revenue of $828.8M and adjusted EPS of $0.37 against a $0.26 consensus, but GAAP EPS came in at $0.05 and shares fell roughly 6% post-print despite a guidance raise.
Acadia Healthcare (NASDAQ: ACHC) filed its Q1 2026 8-K after Wednesday’s close, and on the surface this was a clean beat. Revenue of $828.8 million ran 7.6% above last year and roughly 0.6% above consensus. Adjusted EPS came in at $0.37 against a $0.26 Street estimate, a 39.7% beat. Adjusted EBITDA of $199.5 million blew past the $131.3 million consensus by nearly 52%. Management even nudged full-year adjusted EPS guidance higher to a $1.48 midpoint, a 3.5% raise.
And then the stock fell about 5.9% to roughly $26.60 in the post-print tape.
That gap between the beat and the tape is the entire story of this 8-K. It is not a story about the quarter that just printed. It is a story about what investors are pricing for the next three.
What the filing actually says
The 8-K covers Items 2.02 (results of operations), 7.01 (Reg FD), and 9.01 (financial statements), which is the standard earnings-day disclosure stack — press release, supplemental data, and the conference-call materials Acadia plans to discuss with analysts on April 30 at 9:00 a.m. ET. The data points worth pulling out of the body of the release:
| Metric | Q1 2026 | Notes |
|---|---|---|
| Revenue | $828.8M | +7.6% YoY; ~0.6% above consensus |
| Adjusted EPS | $0.37 | vs. $0.26 consensus (per Zacks via WTOP coverage) |
| GAAP EPS | $0.05 | GAAP net income of $4.1M |
| Adjusted EBITDA | $199.5M | vs. $131.3M consensus |
| Operating margin | ~1.3% | Down from ~5.5% YoY |
| Admissions | 51,959 | Sales-volume growth ~7.1% YoY |
| FY26 revenue guidance | $3.37B–$3.45B | Reconfirmed at ~$3.41B midpoint |
| FY26 adjusted EPS guidance | $1.35–$1.60 | Raised, ~$1.48 midpoint |
| Q2 revenue guide | ~$842.5M | About 2.7% below consensus |
The headline beat is real. So is the gap between adjusted EPS of $0.37 and GAAP EPS of $0.05. A roughly $0.32 reconciliation between the two is wide for a hospital operator, and it tells us Acadia is still carrying meaningful below-the-line items — depreciation, interest on the levered balance sheet, transaction-related expenses, and any non-recurring litigation, regulatory, or settlement costs the company chose to call out as adjustments. The 8-K’s exhibit list is where that detail lives; the SEC EDGAR index page points to the press release and supplemental materials that itemize each adjustment.
Why the tape sold the beat
Three things appear to be at work in the post-print reaction.
First, the Q2 guide. A roughly $842.5 million revenue guide that runs about 2.7% below current sell-side consensus is a meaningful step-down on the next quarter, even as full-year guidance held. That implies the back half has to do more of the heavy lifting, and the market generally discounts back-half-loaded ramps in healthcare-services names that have already had operating-margin pressure.
Second, the operating-margin compression. A drop from roughly 5.5% to 1.3% in operating margin year-over-year is the kind of move that lets a beat-and-raise quarter still feel defensive on the call. The adjusted EBITDA print is strong; the GAAP operating line is not, and that delta will be the focus on Thursday morning’s call.
Third, expectations. ACHC had run hard into the print. The stock was up roughly 99% year-to-date and 26% over the trailing twelve months entering Wednesday, closing at $28.26 before the release. In that setup, a 39% adjusted-EPS beat is a bar that was already partly in the price.
Where this fits in earnings season
ACHC’s print extends a pattern we flagged in our Q1 2026 earnings halftime scorecard — names that beat the headline are still selling off if the forward bar is not raised in line with consensus, especially in segments where multiple compression has already been the dominant 12-month story. Healthcare services has been a relative laggard inside this season’s beats, and behavioral-health pure plays are a small enough basket that single-name moves carry the index for the subsector. For investors who own ACHC inside a diversified equity sleeve rather than as a single-name expression, the print is a reminder that diversification across sub-industries does most of the work risk management is supposed to do at this end of the cycle.
It is also worth flagging the capital-return question. ACHC’s 8-K does not lead with buybacks, and the company is still digesting a multi-year capacity buildout. For investors thinking about how to evaluate that posture against the broader market, our framework on total shareholder yield in 2026 lays out the lens we use.
What we are watching on the call
Three items, in our view, will define the read-through from Thursday’s conference call:
- The reconciliation bridge between adjusted EPS and GAAP EPS. Investors will want clarity on which adjustments are recurring and which are one-time, and whether any litigation, regulatory, or settlement accruals were taken in the quarter.
- Same-facility revenue and patient-day commentary. Headline revenue growth of 7.6% is a function of new beds plus same-facility growth; the mix matters for how the back-half ramp is supposed to compound.
- The shape of the back-half revenue trajectory implied by the FY26 guidance band. With Q1 in the books and a Q2 guide below consensus, the implied second-half run-rate to hit the midpoint becomes the most-watched number.
Forward-looking note: The FY26 guidance ranges, the implied second-half ramp, the conference-call read-through, and the operating-margin trajectory are forward-looking and reflect our current view. Any or all of them may not materialize as described. Investors should treat the numbers as management and third-party projections rather than commitments.
Ferrante Capital LLC is a registered investment adviser. Information presented is for educational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal.
FC and its principals may hold positions in ACHC. This analysis is for educational purposes only and does not constitute a recommendation to buy, sell, or hold any security.
Forward-looking statements reflect Ferrante Capital’s current analysis and involve assumptions and estimates. Actual results may differ materially. Past performance is not indicative of future results.
Please consult a qualified financial professional before making investment decisions.
